Brian Loggie, M.D.

As one of the few experts in peritoneal mesothelioma, Dr. Brian Loggie studies and treats one of the rarest types of cancer, the second most common type of mesothelioma. He is currently the Harold J. Bonstetter Professor of Surgery at the School of Medicine at Creighton University in Omaha, Nebraska. He also holds the position of chief of surgical oncology and the director at Creighton University Medical Center’s Cancer Biology Program.

Dr. Loggie is a widely-respected expert in the field of cancers of the abdominal cavity, including peritoneal mesothelioma. He is also an expert in cancers that are metastatic and has helped to develop novel treatments, like heated intraperitoneal chemotherapy, a once uncommon treatment that is now widely used. He is also the member of several professional organizations and holds several patents from his research.

Areas of Expertise

Dr. Loggie’s areas of expertise mostly include surgical oncology, the surgical treatment of cancers. He also specializes in treating rare cancers and orphan diseases. These include peritoneal mesothelioma, peritoneal carcinomatosis, cutaneous malignant melanoma, pseudomyxoma peritonei, and abdominopelvic and retroperitoneal sarcomas. He also has expertise in managing patient care and treatment for complicated and recurrent tumors.

Education and Early Career

Dr. Loggie’s education began with an undergraduate degree from Loyola College in Montreal, Quebec. He then earned his medical degree at McGill University in Montreal. He completed a surgical residency program at Montreal General Hospital and earned a graduate degree from McGill in experimental surgery. He then went on to complete a clinical and a research fellowship at the University of Illinois at Chicago in surgical oncology.

In his early career, before ending up at Creighton University, Dr. Loggie held faculty positions in Chicago at the University of Illinois, at the Bowman Gray School of Medicine in Winston-Salem, North Carolina, and at the University of Texas Southwestern Medical Center in Dallas, Texas. It was during his time in Winston-Salem, working at the Wake Forest University Baptist Medical Center that he was a leader in the development of a novel new treatment for peritoneal mesothelioma, called HIPEC.

Development of HIPEC

Dr. Loggie is a pioneer of a novel treatment for peritoneal mesothelioma called HIPEC, or heated intraperitoneal chemotherapy. When he began working on this procedure in the early 1990s it was virtually unheard of and not many people were advancing treatments for this rare cancer. The procedure uses surgery to remove the bulk of tumors in the abdominal cavity and then circulates heated chemotherapy drugs to target any remaining cancer cells. It works remarkably well and has given new hope to many patients who thought they had no other options. Today the treatment is almost standard.

Current Position and Research

Dr. Loggie is currently the chief of oncology surgery and a professor at Creighton University where he leads the department, teaches medical students, guides fellowships and residencies, and directs the Cancer Biology Program. He leads and conducts research into rare cancers and diseases, including peritoneal mesothelioma. In addition to his research that helped develop HIPEC, Dr. Loggie also researches genetic factors in mesothelioma and other rare cancers.

Honors and Organizations

With his dedication to treating patients, researching new treatments, and expertise in rare and orphan diseases, Dr. Loggie has become a member of a number of prestigious professional organizations and has won several awards. His memberships include the Royal College of Surgeons of Canada, the Society of Surgical Oncology, the Southeastern Surgical Congress, the American College of Surgeons, the Association for Academic Surgery, the Canadian Association of General Surgeons and several more.

Every year from 2001 to the present, Dr. Loggie has been included as one of the Best Doctors in America. He also won the Creighton University 2010 Magis Award for his work and leadership of a team of surgeons that traveled to Haiti after the massive earthquake. Together the team administered emergency treatment and surgery to victims of the natural disaster.

Any patient with a rare cancer, orphan disease, or peritoneal mesothelioma could benefit from working with Dr. Loggie. His extensive experience and research into these diseases has made him an expert in many areas of medicine that most other doctors know very little about. Many patients with rare diseases or with few other options for treatment turn to Dr. Loggie for hope and excellent care.